Aug 02, 2018
New Research Shows Natural Antioxidant Pycnogenol® Effective in Improving Symptoms of Mild Cognitive Impairment
Jul 25, 2018
BioArctic Announces Detailed Results of the BAN2401 Phase 2b Study in Early Alzheimer's Disease Presented at AAIC 2018
Jul 25, 2018
Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
Jul 25, 2018
Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
Jul 23, 2018
Virtual Reality May Help High School And Medical Students Experience Life With Dementia First Hand
Jul 23, 2018
Pregnancy And Reproductive History May Impact Dementia Risk Plus, The Move To Re-Think The Impact Of Hormone Therapy On Cognition
Jul 05, 2018
BioArctic Announces Positive Topline Results of BAN2401 Phase 2b at 18 Months in Early Alzheimer's Disease
May 22, 2018
Model Estimates Lifetime Risk Of Alzheimer's Dementia Using Biomarkers For Preclinical Disease
Apr 30, 2018
AgeneBio Founder Dr. Michela Gallagher participates in the 2018 Milken Global Conference
Mar 20, 2018
New Alzheimer's Association Report Reveals Sharp Increases in Alzheimer's Prevalence, Deaths and Cost of Care
Feb 26, 2018
Hearing Loss May Be Tied to Memory Loss for Some
Jan 26, 2018
Trump and MoCA Test : Comments by Dr Ziad Nasreddine Test Creator
Dec 28, 2017
Guideline: Exercise May Improve Thinking Ability and Memory
Nov 21, 2017
EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2026
Nov 03, 2017
Mild Cognitive Impairment Markets 2017-2027 - Focus on USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, India, Australia, Brazil, Mexico
Oct 24, 2017
Innovative Alzheimer's Disease Combination Therapy Trial Supported By New Joint Funding Initiative
Sep 27, 2017
Therapix's First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study
Sep 13, 2017
AgeneBio to Receive up to $10 Million in NIH Funding to Advance Program for Mild Cognitive Impairment Due to Alzheimer's Disease
Jun 27, 2017
Araclon Biotech initiates phase II clinical trials of its Alzheimer's vaccine